Schrödinger (NASDAQ:SGDR) announced a strategic collaboration with Eli Lilly and Company (NYSE:LLY) on Friday to integrate Lilly’s high-powered TuneLab™ AI platform directly into Schrödinger’s flagship enterprise software, LiveDesign.
The partnership marks a significant milestone in the "democratization" of drug discovery.
By making TuneLab available in LiveDesign, Schrödinger provides its global biotech customer base with a priority interface to access AI models trained on over $1 billion of Lilly’s proprietary research data.
The integration allows scientists to run advanced predictive workflows—ranging from drug disposition to safety testing—without ever leaving their existing digital workspace.
Lilly launched TuneLab in late 2025 as an "equalizer" for the biotech industry, aiming to provide smaller firms with the same computational firepower used by its internal scientists.
To address the pharmaceutical industry’s strict data-privacy requirements, the platform utilizes federated learning.
This "privacy-first" approach allows partner companies to use and improve Lilly’s models using their own proprietary data while ensuring that the underlying raw data remains separate and secure.
The collaboration follows a similar distribution deal between Lilly and Benchling earlier this week, signaling Lilly’s intent to embed TuneLab into the industry’s most widely used scientific platforms.
For Schrödinger, the move solidifies LiveDesign’s position as a central "operating system" for modern drug discovery, combining its industry-leading physics-based simulations with Lilly’s massive empirical datasets.
Current LiveDesign users are expected to gain access to the TuneLab integration in the first quarter of 2026, with a broader rollout for new users scheduled by the second quarter.